Status:
COMPLETED
C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)
Lead Sponsor:
CSL Behring
Conditions:
Hereditary Angioedema
Eligibility:
All Genders
6+ years
Phase:
PHASE3
Brief Summary
Hereditary angioedema (HAE) is a rare disorder characterized by congenital lack of functional C1 esterase inhibitor. If not treated adequately, the acute attacks of HAE can be life-threatening and may...
Eligibility Criteria
Inclusion
- Key
- Documented congenital C1-INH deficiency
- Acute HAE attack
- Participation in base study CE1145\_3001 (NCT00168103)
- Key
Exclusion
- Acquired angioedema
- Treatment with any other investigational drug besides CE1145 in the last 30 days before study entry
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT00292981
Start Date
August 1 2005
End Date
May 1 2010
Last Update
May 7 2015
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Contact CSL Behring for facility details
Weston, Florida, United States, 33331
2
Contact CSL Behring for facility details
Atlanta, Georgia, United States, 30342
3
Contact CSL Behring for facility details
Idaho Falls, Idaho, United States, 83404
4
Contact CSL Behring for facility details
Chicago, Illinois, United States, 60612-3244